GlassScriptPhysician profile
Peter Ruggiero
NPI 1124022058
$5,905.97
in general payments reported to CMS, 2019-2025
41 companies · $583 in 2025
The $583 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,104 · 2020: $1,015 · 2021: $287 · 2022: $784 · 2023: $851 · 2024: $1,282 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,716.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $818.40 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $814.48 | 2021-2025 | Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $671.13 | 2019-2024 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $559.67 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $455.09 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $445.95 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $357.12 | 2019-2025 | Cuvitru, Takhzyro |
| Pfizer INC. | $139.44 | 2020-2024 | |
| Amarin Pharma, INC. | $119.37 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $114.59 | 2023-2024 | Dupixent |
| Glaxosmithkline, LLC. | $104.54 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $92.68 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $90.63 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $85.16 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $82.74 | 2020-2023 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Ruggiero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.